BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
205 results:

  • 1. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
    Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
    Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory alk-positive NSCLC from a phase II study.
    Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
    Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift.
    Zhang W; Zhang Y; Ouyang WW; Fa Su S; Ma Z; Li QS; Gang Yang W; Xia Chen X; Liu J; Lu B
    Cancer Radiother; 2024 Apr; 28(2):152-158. PubMed ID: 38320903
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy.
    Schoettler ML; Lehmann L; Kao PC; Chen N; Jodele S; Chonat S; Williams KM; London WB; Duncan C; Dandoy C
    Blood Adv; 2024 Mar; 8(5):1220-1233. PubMed ID: 38154068
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Transformation of NSCLC to SCLC harboring EML4-alk fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
    Sun W; Zheng J; Zhou J; Zhou J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.
    Xie X; Zhou M; Wang L; Wang F; Deng H; Yang Y; Sun N; Li R; Chen Y; Lin X; Liu M; Zhou C
    Hum Vaccin Immunother; 2023 Aug; 19(2):2241310. PubMed ID: 37526078
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
    Nakano K
    Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. alk-positive lung adenocarcinoma in a patient with rheumatoid arthritis with long-term treatment for organizing pneumonia: A case report.
    Horie K; Asakura T; Masuzawa K; Terai H; Nakayama S; Suzuki Y
    Medicine (Baltimore); 2022 Dec; 101(49):e32159. PubMed ID: 36626420
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. From the archives of MD Anderson cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
    Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
    Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and alk: Report of Three New Cases in the Head and Neck Region and Literature Review.
    Gallagher KPD; Roza ALOC; Tager EMJR; Mariz BALA; Soares CD; Rocha AC; Abrahão AC; Romañach MJ; Carlos R; Hunter KD; Lopes MA; Vargas PA; Santos-Silva AR
    Head Neck Pathol; 2023 Jun; 17(2):546-561. PubMed ID: 36374445
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions.
    Zeng KL; Abugarib A; Soliman H; Myrehaug S; Husain ZA; Detsky J; Ruschin M; Karotki A; Atenafu EG; Larouche J; Campbell M; Maralani P; Sahgal A; Tseng CL
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):686-695. PubMed ID: 36309076
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Santoro N; Mooyaart JE; Devillier R; Koc Y; Vydra J; Castagna L; Gülbas Z; Martin JD; Araujo MC; Kulagin A; Arat M; Arroyo CH; Martelli MP; Di Ianni M; Hoogenboom JD; de Wreede LC; Ruggeri A; Chabannon C
    Bone Marrow Transplant; 2023 Jan; 58(1):54-60. PubMed ID: 36216975
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Radiotherapy activity in the COVID 19 pandemic: Brazil's operational national-level study.
    Moraes FY; Gouveia AG; Lima RP; Bratti VF; Hamamura AC; Viani GA
    J Cancer Policy; 2023 Jun; 36():100367. PubMed ID: 36216270
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Epithelioid Inflammatory Myofibroblastic Sarcoma with Leukemoid Reaction.
    Wan YY; Miao CL; Liu SB; Zhang T; Luo CH
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1212-1215. PubMed ID: 36089724
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 11.